June 30, 2017 / 7:37 AM / 2 months ago

BRIEF-Valneva confirms its growth strategy and R&D outlook

June 30 (Reuters) - VALNEVA SE:

* REITERATES THAT IT EXPECTS REVENUES TO REACH EUR 105 TO EUR 115 MILLION IN 2017 AND EBITDA OF EUR 5 TO EUR 10 MILLION

* WILL PURSUE ITS STRATEGY TO GROW REVENUES TO AROUND EUR 250 MILLION BY 2020

* EXPECTS TO ANNOUNCE PHASE I RESULTS OF ITS LYME VACCINE CANDIDATE IN H1 2018 AND ACCELERATE PROGRAM'S PROGRESSION WITH VIEW TO STARTING PHASE II IN EARLY 2018

* EXPECTS TO ANNOUNCE SOME IMPORTANT RESEARCH AND DEVELOPMENT MILESTONES IN COMING MONTHS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below